NPD-1335

NPD1335 is a Trypanosoma brucei phosphodiesterase B1 (TbrPDEB1) inhibitor with submicromolar activities against T. brucei parasites. NPD1335 displays a greatly improved cytotoxicity profile. NPD1335 increases intracellular cAMP levels and results in the distortion of the cell cycle and cell death[1]. NPD-1335 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Product Specifications

CAS Number

[2376326-31-5]

UNSPSC

12352005

Target

Parasite; Phosphodiesterase (PDE)

Type

Reference compound

Related Pathways

Anti-infection; Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Infection; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/npd1335.html

Purity

98.10

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(NCC1=CC=CC=C1)C#CC2=CC(C3=NN(C(C)C)C([C@@]4([H])CC=CC[C@@]34[H])=O)=CC=C2OC

Molecular Formula

C28H29N3O3

Molecular Weight

455.55

References & Citations

[1]de Heuvel E, et al. Alkynamide phthalazinones as a new class of TbrPDEB1 inhibitors (Part 2) . Bioorg Med Chem. 2019 Jul 5. pii: S0968-0896 (19) 30790-4.|[2]Erik de Heuvel, et al. Alkynamide phthalazinones as a new class of TbrPDEB1 inhibitors (Part 2) . Bioorg Med Chem. 2019 Jul 5. pii: S0968-0896 (19) 30790-4.